<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39464754</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2501-2533</ISSN><JournalIssue CitedMedium="Internet"><Volume>68</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Season>Jul-Sep</Season></PubDate></JournalIssue><Title>Romanian journal of ophthalmology</Title><ISOAbbreviation>Rom J Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>One-time low concentration betadine eye wash: A novel treatment for epidemic viral conjunctivitis for accelerated recovery.</ArticleTitle><Pagination><StartPage>268</StartPage><EndPage>273</EndPage><MedlinePgn>268-273</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.22336/rjo.2024.49</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">This study aims to renew the management of viral epidemic conjunctivitis by introducing a one-time, low-concentration ocular surface povidone-iodine (LOS-pI) wash.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Among the 3,002 patients screened, 1,328 with acute conjunctivitis were categorized into two groups. Group A (664 patients) underwent a 1% betadine wash in addition to the standard treatment protocol (Eye Lubricant + Moxifloxacin 0.5% eyedrops), while Group B (664 patients) followed the standard protocol alone. In cases of membranous conjunctivitis, manual membrane removal was performed. Treatment responses were observed daily for three days, followed by weekly assessments for two additional weeks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Co-infection of adenovirus with enterovirus was found to be the main cause, often accompanied by staphylococcal superinfection. Group A showed complete resolution of conjunctival inflammation, with a remarkable 76.05% of patients experiencing improvement within an average of 2.6±0.51 days, in contrast to Group B's average of 7.5±1.1 days (p &lt;0.05). Additionally, 13% of Group B patients with recalcitrant conjunctivitis significantly recovered following the 1% betadine wash. Complications (subconjunctival hemorrhage: 34.04%, superficial punctate keratitis: 6.02%) were more prevalent in Group B.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">The authors hypothesized that a single wash with betadine is sufficient to reduce disease duration and prevent secondary infections and complications. The core strength of our study lies in its substantial sample size. To our knowledge, no similar previous research has been conducted, on such a larger scale.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Viral conjunctivitis brings discomfort, work absenteeism, and financial burden. A single low-concentration betadine wash expedites recovery and reduces complications in acute infective conjunctivitis. This approach significantly enhances patient outcomes and alleviates the socioeconomic impact of the condition.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vats</LastName><ForeName>Sumedha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Armed Forces Clinic, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tripathi</LastName><ForeName>Anchal</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Military Hospital, Jammu, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Inam Danish</ForeName><Initials>ID</Initials><AffiliationInfo><Affiliation>Department of Clinical Microbiology and Infectious Diseases, Armed Forces Clinic, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhull</LastName><ForeName>Pawan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>DNB Neurology, Armed Forces Clinic, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Sanjay Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Army Hospital Research and Referral, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goenka</LastName><ForeName>Ranjit</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Base Hospital Delhi Cantt, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vats</LastName><ForeName>Devendra Paul</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Maharaja Agrasen Medical College, Agroha, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>Rom J Ophthalmol</MedlineTA><NlmUniqueID>101677459</NlmUniqueID><ISSNLinking>2457-4325</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>85H0HZU99M</RegistryNumber><NameOfSubstance UI="D011206">Povidone-Iodine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000891">Anti-Infective Agents, Local</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009883">Ophthalmic Solutions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011206" MajorTopicYN="Y">Povidone-Iodine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003236" MajorTopicYN="Y">Conjunctivitis, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000891" MajorTopicYN="Y">Anti-Infective Agents, Local</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009883" MajorTopicYN="Y">Ophthalmic Solutions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015828" MajorTopicYN="N">Eye Infections, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adenovirus</Keyword><Keyword MajorTopicYN="N">betadine wash</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">epidemic conjunctivitis</Keyword><Keyword MajorTopicYN="N">staphylococcus</Keyword><Keyword MajorTopicYN="N">viral conjunctivitis</Keyword></KeywordList><CoiStatement>The authors state no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>28</Day><Hour>5</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39464754</ArticleId><ArticleId IdType="pmc">PMC11503237</ArticleId><ArticleId IdType="doi">10.22336/rjo.2024.49</ArticleId><ArticleId IdType="pii">RomJOphthalmol-68-268</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Azari AA, Arabi A. Conjunctivitis: A Systematic Review. J Ophthalmic Vis Res. 2020;15:372–395.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7431717</ArticleId><ArticleId IdType="pubmed">32864068</ArticleId></ArticleIdList></Reference><Reference><Citation>Azari AA, Barney NP. Conjunctivitis: a systematic review of diagnosis and treatment. JAMA. 2013;310:1721–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049531</ArticleId><ArticleId IdType="pubmed">24150468</ArticleId></ArticleIdList></Reference><Reference><Citation>Keen M, Thompson M. Treatment of Acute Conjunctivitis in the United States and Evidence of Antibiotic Overuse: Isolated Issue or a Systematic Problem? Ophthalmology. 2017;124:1096–1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28734327</ArticleId></ArticleIdList></Reference><Reference><Citation>Udeh BL, Schneider JE, Ohsfeldt RL. Cost effectiveness of a point-of-care test for adenoviral conjunctivitis. Am J Med Sci. 2008;336:254–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">18794621</ArticleId></ArticleIdList></Reference><Reference><Citation>Rietveld RP, ter Riet G, Bindels PJ, Schellevis FG, van Weert HC. Do general practitioners adhere to the guideline on infectious conjunctivitis? Results of the Second Dutch National Survey of General Practice BMC Fam Pract. 2007;8:54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2034564</ArticleId><ArticleId IdType="pubmed">17868475</ArticleId></ArticleIdList></Reference><Reference><Citation>Everitt H, Little P. How do GPs diagnose and manage acute infective conjunctivitis? A GP survey. Fam Pract. 2002;19:658–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pihos AM. Epidemic keratoconjunctivitis: a review of current concepts in management. J Optom. 2013;6:69–74.</Citation></Reference><Reference><Citation>Shorter E, Whiteside M, Harthan J, Margolis MS, Hartwick AT, Johnson S, et al. Safety and tolerability of a one-time, day-care administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: The Reducing Adenoviral Patient Infected Days (RAPID) study. Ocul Surf. 2019;17:828–832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6874762</ArticleId><ArticleId IdType="pubmed">31401340</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg SJ, Apt L, Valenton M, Del Signore M, Cubillan L, Labrador MA, et al. A controlled trial of povidone-iodine to treat infectious conjunctivitis in children. Am J Ophthalmol. 2002;134:681–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12429243</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamora JL. Chemical and microbiologic characteristics and toxicity of povidone-iodine solutions. Am J Surg. 1986;151:400–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">3513654</ArticleId></ArticleIdList></Reference><Reference><Citation>Saggers BA, Stewart GT. Polyvinyl-pyrrolidone-iodine: an assessment of antibacterial activity. Epidemiol Infect. 1964;62:509–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2134614</ArticleId><ArticleId IdType="pubmed">14239927</ArticleId></ArticleIdList></Reference><Reference><Citation>Eggers M. Infectious disease management and control with povidone iodine. Infect Dis Ther. 2019;8:581–93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6856232</ArticleId><ArticleId IdType="pubmed">31414403</ArticleId></ArticleIdList></Reference><Reference><Citation>Grzybowski A, Kanclerz P, Myers WG. The use of povidone-iodine in ophthalmology. Curr Opin Ophthalmol. 2018;29:19–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">28984794</ArticleId></ArticleIdList></Reference><Reference><Citation>Edington M, Ramaesh K, Lockington D. Virucidal benefits of povidone-iodine use on the ocular surface: a review. BMJ Open Ophthalmol. 2020;5:e000509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7406023</ArticleId><ArticleId IdType="pubmed">32818151</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>